AbbVie sees positive late-stage results for lutikizumab in hidradenitis suppurativa (ABBV:NYSE)

AbbVie (ABBV) reported positive phase 3 results for lutikizumab in treating hidradenitis suppurativa, with 31.4% of patients achieving HiSCR75 at week 16. The treatment also met secondary goals, including pain reduction and fewer flares. More data and regulatory filings are expected in 2027.

AbbVie's experimental hidradenitis suppurativa drug, lutikizumab, succeeded in a Phase 3 trial but missed market expectations. 31.4% of patients showed significant improvement compared to 23.4% in the placebo group. The drug met all secondary endpoints and was well tolerated, according to the company.

MoonLake Immunotherapeutics (MLTX) shares rose 18% after AbbVie (ABBV) reported Phase 3 trial results for a competing hidradenitis suppurativa drug. AbbVie's lutikizumab showed an 8-point improvement over placebo, which RBC Capital deemed underwhelming. MoonLake's sonelokimab previously demonstrated a 14-point improvement in a similar trial. MoonLake awaits FDA review of its drug application, submitted on Sept. 30, with a potential US launch in late 2027.

AbbVie (ABBV) reported positive phase 3 trial results for lutikizumab, a treatment for hidradenitis suppurativa, meeting its primary endpoint. The company has a 2.36% dividend yield, an 85% payout ratio, and a 5.2% 3-year dividend growth rate. Its GF Value suggests the stock is 27.5% overvalued. AbbVie's GF Score is 76, indicating strong profitability but weaker financial strength and momentum.

AbbVie reported positive Phase III results for lutikizumab, a treatment for Verneuil's disease. The trial met primary and secondary endpoints, showing significant clinical responses and safety. Lutikizumab improved patients' quality of life and symptom control. AbbVie's net sales are primarily from the US (76.2%).

AbbVie (ABBV) reported positive Phase 3 INTREPID trial results for lutikizumab, showing significant improvement in hidradenitis suppurativa (HS) symptoms. The drug met primary and 8 secondary endpoints, including reduced skin pain and fewer disease flares, with a safety profile similar to placebo. The data will support regulatory submissions in 2027.